

Announcement from the extra general meeting in Xbrane Biopharma

The extra general meeting in Xbrane Biopharma AB ("Xbrane" or the "Company") was held today on 22 September 2020 and the following resolutions were passed by the meeting.

Amendments of the Company's articles of association

The extra general meeting resolved, in accordance with the boards' proposal, to amend the Company's articles of association regarding, inter alia, the limits for the share capital to a minimum of SEK 4,322,465 and a maximum of SEK 17,289,860 and the limits for the number of shares to a minimum of 19,280,707 and a maximum of 77,122,828. It was further resolved to amend the clause regarding attendance at general meetings due to a change in the Swedish Companies Act.

Authorization regarding issuances

The extra general meeting resolved, in accordance with the boards' proposal, to authorize the board of directors during the period up until the next annual general meeting, on one or more occasions, to resolve to issue shares, convertibles and/or warrants, with or without preferential rights for the shareholders, corresponding to not more than 20 percent of the share capital of the Company after completed issuances based on the number of shares at the time of the extra general meeting, to be paid in cash, in kind and/or by way of set-off. The purpose for the board to resolve on issuances with deviation from the shareholders preferential rights in accordance with the above is primarily for the purpose to broaden the shareholder base, raise new capital to increase flexibility of the Company or in connection with acquisitions. If issuances are carried out with deviation from the shareholders' preferential rights, such issue shall be made in accordance with customary market terms.

For detailed terms regarding the above resolution at the extra general meeting, reference is made to the notice and complete proposals that are available on the Company's website, www.xbrane.com.

Contacts

Martin Åmark, CEO/ IR

M: +46 (0) 763-093 777

E: martin.amark@xbrane.com

About Us

Xbrane Biopharma AB develops biological drugs based on a platform technology that provides significantly lower production costs compared to competing systems. Xbrane's leading product Xlucane, a Lucentis® biosimilar candidate, addresses the €10.4b ophthalmic VEGFa inhibitor market. Xlucane is in phase III and marketing authorization is expected mid-2022. Xbrane has additionally four biosimilars in its pipeline targeting €8.7b in originator sales. Xbrane's head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit www.xbrane.com.

Attachments

[Announcement from the extra general meeting in Xbrane Biopharma](#)